Acute Myeloid Leukemia Stocks List

Recent Signals

Date Stock Signal Type
2019-10-18 APRE New 52 Week Closing High Bullish
2019-10-18 APRE New 52 Week High Strength
2019-10-18 ARAV 50 DMA Resistance Bearish
2019-10-18 ARGX 20 DMA Support Bullish
2019-10-18 ATNM MACD Bullish Signal Line Cross Bullish
2019-10-18 ATNM 20 DMA Resistance Bearish
2019-10-18 BLRX 20 DMA Resistance Bearish
2019-10-18 BLRX 50 DMA Resistance Bearish
2019-10-18 BLRX Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2019-10-18 CLLS Fell Below 20 DMA Bearish
2019-10-18 CTIC Crossed Above 20 DMA Bullish
2019-10-18 FBIO MACD Bullish Signal Line Cross Bullish
2019-10-18 GMAB Narrow Range Bar Range Contraction
2019-10-18 MBRX 50 DMA Resistance Bearish
2019-10-18 MBRX Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2019-10-18 MBRX 20 DMA Support Bullish
2019-10-18 MRUS Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2019-10-18 MRUS NR7 Range Contraction
2019-10-18 NK 200 DMA Resistance Bearish
2019-10-18 NK Fell Below 20 DMA Bearish
2019-10-18 NK MACD Bearish Signal Line Cross Bearish
2019-10-18 SNSS Stochastic Reached Oversold Weakness
2019-10-18 SNSS NR7 Range Contraction
2019-10-18 TRIL Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2019-10-18 TRIL 20 DMA Resistance Bearish
2019-10-18 TRIL Pocket Pivot Bullish Swing Setup
2019-10-18 TROV Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2019-10-18 TROV NR7 Range Contraction

Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with normal blood cells. Symptoms may include feeling tired, shortness of breath, easy bruising and bleeding, and increased risk of infection. Occasionally spread may occur to the brain, skin, or gums. As an acute leukemia, AML progresses rapidly and is typically fatal within weeks or months if left untreated.Risk factors include smoking, previous chemotherapy or radiation therapy, myelodysplastic syndrome, and exposure to the chemical benzene. The underlying mechanism involves replacement of normal bone marrow with leukemia cells, which results in a drop in red blood cells, platelets, and normal white blood cells. Diagnosis is generally based on bone marrow aspiration and specific blood tests. AML has several subtypes; for which treatments and outcomes may vary.AML, typically is initially treated with chemotherapy aimed at inducing remission. People may then go on to receive additional chemotherapy, radiation therapy, or a stem cell transplant. The specific genetic mutations present within the cancer cells may guide therapy, as well as determine how long that person is likely to survive. Arsenic trioxide may be tried in cases that have recurred following usual treatments.AML affected about one million people globally in 2015 and resulted in 147,000 deaths. It most commonly occurs in older adults. Males are affected more often than females. AML is curable in about 35% of people under 60 years old and 10% over 60 years old. Older people who are not healthy enough to receive intensive chemotherapy have a typical survival of 5–10 months. It accounts for roughly 1.8% of cancer deaths in the United States.

More about Acute Myeloid Leukemia